Levetiracetam (Epilepsy)

ADHD (Attention deficit hyperactivity disorder): Risk

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S7511
R25081		 Huber-Mollema (Levetiracetam), 2019 ADHD total (Social Emotional Questionnaire) (Completed by mothers) Clinical cutoff throughout pregnancy prospective cohort exposed to other treatment, sick Adjustment: No 1.26 [0.23;6.89] C 2/28   5/87 7 28
ref
S7308
R28372		 Bromley (Levetiracetam), 2016 Maladaptive behavior: Attention (BASC) (5-9 years old) during pregnancy (anytime or not specified) retrospective cohort (registry) unexposed, sick Adjustment: No extrapolated (cont. endpoint) 0.86 [0.41;1.78] -/42   -/55 - 42
ref
Total 2 studies 0.91 [0.47;1.79] 7 70
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Huber-Mollema (Levetiracetam), 2019Huber-Mollema, 2019 1 1.26[0.23; 6.89]72816%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: criticalROB mesure: moderateROB reporting: moderate Bromley (Levetiracetam), 2016Bromley, 2016 2 0.86[0.41; 1.78]-4284%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 0.91[0.47; 1.79]7700.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Levetiracetam; 2: Levetiracetam;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.91[0.47; 1.79]7700%NAHuber-Mollema (Levetiracetam), 2019 Bromley (Levetiracetam), 2016 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 0.86[0.41; 1.79]-42 -NABromley (Levetiracetam), 2016 1 exposed to other treatment, sickexposed to other treatment, sick 1.26[0.23; 6.89]728 -NAHuber-Mollema (Levetiracetam), 2019 1 Tags Adjustment   - No  - No 0.91[0.47; 1.79]7700%NAHuber-Mollema (Levetiracetam), 2019 Bromley (Levetiracetam), 2016 2 extrapolated (cont. endpoint)extrapolated (cont. endpoint) 0.86[0.41; 1.79]-42 -NABromley (Levetiracetam), 2016 1 All studiesAll studies 0.91[0.47; 1.79]7700%NAHuber-Mollema (Levetiracetam), 2019 Bromley (Levetiracetam), 2016 20.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 0.86[0.41; 1.79]-42 -NABromley (Levetiracetam), 2016 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.26[0.23; 6.89]728 -NAHuber-Mollema (Levetiracetam), 2019 10.510.01.0